
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets A preferred …